Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 328,763
  • Shares Outstanding, K 87,437
  • Annual Sales, $ 2,560 K
  • Annual Income, $ -37,450 K
  • EBIT $ -99 M
  • EBITDA $ -98 M
  • 60-Month Beta 0.43
  • Price/Sales 1.79
  • Price/Cash Flow N/A
  • Price/Book 1.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.24
  • Low Estimate -0.56
  • Prior Year -6.01
  • Growth Rate Est. (year over year) +94.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.83 +46.64%
on 02/18/26
4.16 -0.24%
on 03/09/26
+0.60 (+16.90%)
since 02/09/26
3-Month
2.83 +46.64%
on 02/18/26
4.55 -8.89%
on 12/24/25
+0.51 (+14.01%)
since 12/09/25
52-Week
1.35 +207.41%
on 08/11/25
10.67 -61.11%
on 03/12/25
-6.40 (-60.68%)
since 03/07/25

Most Recent Stories

More News
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the management...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals: Q3 Earnings Snapshot

X4 Pharmaceuticals: Q3 Earnings Snapshot

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial Previously announced workforce reductions resulted in $13M annualized cost savings...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced...

XFOR : 4.15 (+10.37%)
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced...

XFOR : 4.15 (+10.37%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 4.77
2nd Resistance Point 4.46
1st Resistance Point 4.31
Last Price 4.15
1st Support Level 3.85
2nd Support Level 3.54
3rd Support Level 3.39

See More

52-Week High 10.67
Fibonacci 61.8% 7.11
Fibonacci 50% 6.01
Fibonacci 38.2% 4.91
Last Price 4.15
52-Week Low 1.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar